FORMULATIONS OF ENZALUTAMIDE
This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
1 - 82 . (canceled)
83 . A solid pharmaceutical composition comprising a solid dispersion containing amorphous enzalutamide and a polymer, wherein the polymer is hydroxypropyl methylcellulose acetate succinate.
84 - 86 . (canceled)
87 . The solid pharmaceutical composition according to claim 83 , wherein the amount of the polymer is 0.5 to 7 parts by weight, with respect to 1 part by weight of the enzalutamide.
88 . The solid pharmaceutical composition according to claim 83 , wherein the amount of the polymer is 0.5 to 3 parts by weight, with respect to 1 part by weight of the enzalutamide.
89 . The solid pharmaceutical composition according to claim 83 , wherein the amount of the polymer is 3 to 5 parts by weight, with respect to 1 part by weight of the enzalutamide.
90 . The solid pharmaceutical composition according to claim 83 , wherein the amount of the polymer is 3 parts by weight, with respect to 1 part by weight of the enzalutamide.
91 . The solid pharmaceutical composition according to claim 83 , wherein the amount of the polymer is 5 parts by weight, with respect to 1 part by weight of the enzalutamide.
92 . The solid pharmaceutical composition according to claim 83 , which the solubility of enzalutamide is twice or more compared to that of enzalutamide.
93 - 95 . (canceled)
96 . The solid pharmaceutical composition according to claim 83 , which is a tablet.